Cytek Biosciences
CTKB51
$5.10arrow_drop_up3.86%$0.19
Penny Stock
CTKB51
$5.10
arrow_drop_up3.86%Performance History
| Key Stats | |
|---|---|
| Open | $4.94 |
| Prev. Close | $4.91 |
| EPS | -0.14 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | $645.69M |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 4.88 | 5.01 |
| 52 Week Range | 3.80 | 9.87 |
| Ratios | |
|---|---|
| EPS | -0.14 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
About Cytek Biosciences (CTKB)
- Sector
- Healthcare
- Industry
- Medical Devices
- CEO
- Dr. Wenbin Jiang Ph.D.
- Headquarters
- Fremont
- Employees
- 699
- Exchange
- NASDAQ
Keep an eye on Cytek Biosciences
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is Cytek Biosciences's (CTKB) price per share?
The current price per share for Cytek Biosciences (CTKB) is $5.1. The stock has seen a price change of $0.19 recently, indicating a 3.87% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Cytek Biosciences (CTKB)?
For Cytek Biosciences (CTKB), the 52-week high is $9.87, which is 93.53% from the current price. The 52-week low is $3.8, the current price is 34.21% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Cytek Biosciences (CTKB) a growth stock?
Cytek Biosciences (CTKB) has shown an average price growth of 0.41% over the past three years. It has received a score of 26 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Cytek Biosciences as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Cytek Biosciences (CTKB) stock price performance year to date (YTD)?
As of the latest data, Cytek Biosciences (CTKB) has a year-to-date price change of -42.5%. Over the past month, the stock has experienced a price change of -5.73%. Over the last three months, the change has been -10.21%. Over the past six months, the figure is -26.62%.
help
Is Cytek Biosciences (CTKB) a profitable company?
Cytek Biosciences (CTKB) has a net income of -$12.15M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 56.69% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -18.29% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $193.02M, with a revenue growth rate of 17.67%, providing insight into the company's sales performance and growth. The gross profit is $109.43M. Operating income is noted at -$26.34M. Furthermore, the EBITDA is -$17.41M.
help
What is the market capitalization of Cytek Biosciences (CTKB)?
Cytek Biosciences (CTKB) has a market capitalization of $645.69M. The average daily trading volume is 696.38K, indicating the stock's liquidity and investor engagement.
News
6/24/2024
Cytek Biosciences (CTKB) Moves 5.1% Higher: Will This Strength Last?
HEALTH
PRODUCT / SERVICES ANNOUNCEMENT
5/28/20241-Laser and 2-Laser 6-Color TBNK Reagents from Cytek® Biosciences Approved for Clinical Use in China
PRODUCT / SERVICES ANNOUNCEMENT
5/20/2024Cytek® Biosciences Adds Ability to Detect Subcellular Particles to Its Industry-Leading Cell Analysis Systems
5/8/2024
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Tops Revenue Estimates
EARNINGS RELEASES AND OPERATING RESULTS
5/8/2024Cytek Biosciences Reports First Quarter 2024 Financial Results
5/7/2024
Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates